• Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML 

  Basheer, F; Giotopoulos, G; Meduri, E; Yun, H; Mazan, M; Sasca, D; Gallipoli, P; Marando, L; Gozdecka, M; Asby, R (Rockefeller University Press, 2019-03-19)

  Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the ...

• Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring 

  Hijazi, M; Smith, R; Rajeeve, V; Bessant, C; Cutillas, PR (Nature Publishing, 2020-01-20)

  Understanding how oncogenic mutations rewire regulatory-protein networks is important for rationalizing the mechanisms of oncogenesis and for individualizing anticancer treatments. We report a chemical phosphoproteomics ...

• Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1BCR-ABL-JAK2 Complex 

  Chen, M; Gallipoli, P; DeGeer, D; Sloma, I; Forrest, DL; Chan, M; Lai, D; Jorgensen, H; Ringrose, A; Wang, HM (2013-03)

• A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression 

  Giotopoulos, G; van der Weyden, L; Osaki, H; Rust, AG; Gallipoli, P; Meduri, E; Horton, SJ; Chan, W-I; Foster, D; Prinjha, RK (2015-09-21)

• IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. 

  Odabashian, M; Carlotti, E; Araf, S; Okosun, J; Spada, F; Gribben, JG; Forconi, F; Stevenson, FK; Calaminici, M; Krysov, S (2020-03-12)

  Follicular lymphoma B cells undergo continuous somatic hypermutation (SHM) of their immunoglobulin variable region genes, generating a heterogeneous tumor population. SHM introduces DNA sequences encoding N-glycosylation ...

• Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2-Mutated MDS/AML 

  Al Seraihi, A; Rio-Machin, A; Tawana, K; Boedoer, C; Araf, S; Heward, JA; Smith, M; Iqbal, S; Best, S; Lea, N (2016-12-02)

• Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma 

  Mansouri, L; Noerenberg, D; Young, E; Mylonas, E; Abdulla, M; Frick, M; Asmar, F; Ljungstroem, V; Schneider, M; Yoshida, K (2016-12-08)

• A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia 

  Tzelepis, K; Koike-Yusa, H; De Braekeleer, E; Li, Y; Metzakopian, E; Dovey, OM; Mupo, A; Grinkevich, V; Li, M; Mazan, M (2016-10-18)

• Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR. 

  Ortega-Molina, A; Deleyto-Seldas, N; Carreras, J; Sanz, A; Lebrero-Fernández, C; Menéndez, C; Vandenberg, A; Fernández-Ruiz, B; Marín-Arraiza, L; de la Calle Arregui, C (2019-08)

  The humoral immune response demands that B cells undergo a sudden anabolic shift and high cellular nutrient levels which are required to sustain the subsequent proliferative burst. Follicular lymphoma (FL) originates from ...

• SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4 

  Tzelepis, K; De Braekeleer, E; Aspris, D; Barbieri, I; Vijayabaskar, MS; Liu, W-H; Gozdecka, M; Metzakopian, E; Toop, HD; Dudek, M (2018-12-19)

• Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma 

  Okosun, J; Bödör, C; Wang, J; Araf, S; Yang, CY; Pan, C; Boller, S; Cittaro, D; Bozek, M; Iqbal, S (2014-02-01)

  Follicular lymphoma is an incurable malignancy, with transformation to an aggressive subtype representing a critical event during disease progression. Here we performed whole-genome or whole-exome sequencing on 10 follicular ...

• Rituximab as a first step in tackling transformation 

  Okosun, J; Kridel, R; Fitzgibbon, J (2018-08)

• The routes for transformation of follicular lymphoma 

  Okosun, J; Montoto, S; Fitzgibbon, J (2016-07)

• Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs 

  Matasar, MJ; Luminari, S; Barr, PM; Barta, SK; Danilov, AV; Hill, BT; Phillips, TJ; Jerkeman, M; Magagnoli, M; Nastoupil, LJ (2019-11)

• Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions. 

  Guitart, AV; Panagopoulou, TI; Villacreces, A; Vukovic, M; Sepulveda, C; Allen, L; Carter, RN; van de Lagemaat, LN; Morgan, M; Giles, P (2017-03-06)

  Strict regulation of stem cell metabolism is essential for tissue functions and tumor suppression. In this study, we investigated the role of fumarate hydratase (Fh1), a key component of the mitochondrial tricarboxylic ...

• Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial 

  Sehn, LH; Chua, N; Mayer, J; Dueck, G; Trneny, M; Bouabdallah, K; Fowler, N; Delwail, V; Press, O; Salles, G (2016-08)

• Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study 

  Snowden, JA; Hawkey, C; Hind, D; Swaby, L; Mellor, K; Emsley, R; Mandefield, L; Lee, E; Badoglio, M; Polge, E (2019-05-31)

• Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility 

  Angulo-Urarte, A; Casado, P; Castillo, SD; Kobialka, P; Kotini, MP; Figueiredo, AM; Castel, P; Rajeeve, V; Mila-Guasch, M; Millan, J (2018-11-16)

• Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR 

  Mogilenko, DA; Haas, JT; L'homme, L; Fleury, S; Quemener, S; Levavasseur, M; Becquart, C; Wartelle, J; Bogomolova, A; Pineau, L (2019-05-16)

• Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. 

  Wang, H-Q; Jia, L; Li, Y-T; Farren, T; Agrawal, SG; Liu, F-T (2019-01-08)

  Chronic lymphocytic leukemia (CLL) remains incurable with current standard therapy. We have previously reported that an increased expression of interleukin-6 (IL-6) receptor CD126 leads to resistance of CLL cells to ...

View more